KLAS Contact
Contact KLAS
Contact KLAS
2024 BEST IN KLAS
Preferences
Related Series
2014
2013
2012
2011
2010
2008
2006
MR 1.5 T Product Comparison Report 2014
BOTTOM LINES MRI 2013: Sorting Through the Noise
GE HEALTHCARE
More communicative sales and contracting. Room to improve nickel-and-diming as they price more aggressively. Silent MR is resonating with  GE and non-GE users.  Praised for the IntelliTouch patient locator. Multiple reports of issues with the detachable table, though not debilitating.
PHILIPS
Strong praise for the dStream coils. Users excited about the achieved results as well as the future ability to not add channels to the system. Highest-priced scanner in the report, and providers report it is worth the cost. High levels of support and communication had by initial Ingenia customers have not been maintained. One customer cites support has changed to a message and callback approach.
SIEMENS
The MRI technology leader. Improved training and account management— Siemens’ representatives more invested in providers’ success. Aera users leading the way in cardiac MR. Siemens’ Dot engines great for lesser-used protocols but can be restrictive when the providers get more specialized protocols.
TOSHIBA
Providers want the Titan to be easier to use. M-Power user interface has brought some improvements but still requires too many clicks and too much tech interaction. Support and account management are traditional Toshiba strengths but are now the weakest in the group. Strong  implementations and great training. Pianissimo gradients provide quiet scanning across the board.
Project Manager
Robert Ellis
This material is copyrighted. Any organization gaining unauthorized access to this report will be liable to compensate KLAS for the full retail price. Please see the KLAS DATA USE POLICY for information regarding use of this report. © 2024 KLAS Research, LLC. All Rights Reserved. NOTE: Performance scores may change significantly when including newly interviewed provider organizations, especially when added to a smaller sample size like in emerging markets with a small number of live clients. The findings presented are not meant to be conclusive data for an entire client base.